Latest Articles

In France, transparency requirements are regulated by two main sets of laws: “The French Anti-Gift Law” regulates the provision of gifts, discounts and other incentives to health care providers by life sciences companies, while “the French Sunshine Act” imposes disclosure obligations on companies relating to benefits granted to, and agreements concluded with, health care providers. While the French Sunshine Act has been frequently amended to reflect subsequent changes brought by implementing decrees, orders, and circulars,…
French parliamentarians are considering landmark anti-corruption laws that would be a considerable breakthrough for those in the fight against corruption. The French Constitutional Council must vote on the legislation within one month, and even if it is ruled invalid there are steps to be taken to keep the legislation alive. Some of the changes include a French anti-corruption Agency headed by a Magistrate, new law forcing French companies to implement a compliance program, and a…
Following the CJEU’s judgment of October 2015 invalidating the European Commission’s Safe Harbor Decision, the Data Protection Authority Hamburg (“DPA Hamburg“) started investigations against 35 internationally operating companies in Hamburg. According to a press release of DPA Hamburg of 6 June 2016, these investigations revealed that the majority of the companies under investigation had used the six months grace period, as set by the Article 29 Working Party, to change their practices to be based…
The options available to EU organisations for lawfully transferring personal data from Europe to the United States appear to be dwindling. In particular, there have been further setbacks to the approval of the Privacy Shield and, separately, a new legal challenge to the validity of EU model contract clauses. For more information click here to read our issued Client Alert.…
The long-awaited General Data Protection Regulation was published in the Official Journal of the European Union on 4 May 2016. This means that the most comprehensive reform to the EU’s omnibus data protection law in 20 years will apply throughout the European Union from 25 May 2018. We have written in previous posts (here and here) about the key differences being brought in by the GDPR, and the likely impact on businesses. The impact of…
The European Commission has published its draft adequacy decision on the EU-U.S. Privacy Shield, the proposed data transfer framework that would replace the defunct Safe Harbor program. The draft adequacy decision formally supports the view that the proposed EU-U.S. Privacy Shield will ensure an adequate level of protection for the transfer of personal data from the EU to U.S. companies which enlist in the new program. The draft decision also provides full details of the…
In the latest step toward finalising a replacement for the defunct Safe Harbor program, the European Commission has published its draft adequacy decision, formally supporting its view that the proposed EU-U.S. Privacy Shield will ensure an adequate level of protection for the transfer of personal data from the EU to U.S. companies which enlist in the program. It also introduces a range of enhanced rights and redress mechanisms for EU citizens. Once finalised, an adequacy…
President Obama signed the U.S. Judicial Redress Act (JRA) into law on 24 February 2016, giving European citizens the same right as U.S. citizens to bring actions against the U.S. government if their personal data are misused. While the JRA is not a formal prerequisite to finalizing the EU-U.S. Privacy Shield transatlantic data-sharing framework, it’s considered to be a key step in this direction – which means it’s highly relevant for businesses with transatlantic…
The U.S. Judicial Redress Act has been signed into law by President Obama. The move marks an important step in data transfer relations between the EU and the United States, gives the green light to the EU-U.S. law enforcement data Umbrella Agreement and helps to underpin the Privacy Shield. Click here to read more in the issued Client Alert.…
We’ve covered the French Sunshine Act, which requires French pharmaceutical companies to disclose their links to healthcare providers, extensively over the past few years and most recently here. France on the whole, however, has been lagging behind many other countries when it comes to anti-corruption laws. It looks like that’s about to change in ways that could have considerable impact for life sciences companies operating in the country. France has started examining draft legislation…